- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 19, 1992
Highlights
- Market Cap
- $1.03M
- Enterprise Value
- -$7.59M
- EPS (TTM)
- -$23.80
- Gross Profit (TTM)
- -$69.00K
- EBITDA (TTM)
- -$11.25M
- Year Range
- $3.18 - $71.50
- ROA (TTM)
- -108.01%
- ROE (TTM)
- -166.02%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $8.77M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ERNA Performance Chart
Eterna Therapeutics Inc (ERNA) is down 89.1% since the beginning of the year. At $3 per share, ERNA is trading 95.4% below its 52-week high of $71. Investors who bought $1,000 worth of ERNA shares 5 years ago would now be looking at an investment worth $0.
Loading charts...
Compare this symbol against anything
Returns By Period
Eterna Therapeutics Inc (ERNA) has returned -89.07% so far this year and -91.59% over the past 12 months. Over the last ten years, ERNA has returned -64.30% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Eterna Therapeutics Inc
- 1D
- -5.48%
- 1M
- -47.69%
- 6M
- -89.25%
- YTD
- -89.07%
- 1Y
- -91.59%
- 3Y*
- -85.19%
- 5Y*
- -86.94%
- 10Y*
- -64.30%
- ALL TIME*
- -33.20%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ERNA Monthly Returns History
Based on dividend-adjusted daily data since Oct 19, 1992, ERNA's average daily return is +0.07%, while the average monthly return is +2.66%. At this rate, an investment would double in approximately 2.2 years.
Historically, 41% of months were positive and 59% were negative. The best month was Apr 2021 with a return of +1,238.7%, while the worst month was Feb 2026 at -76.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 14 months.
On a daily basis, ERNA closed higher 40% of trading days. The best single day was Jun 16, 2020 with a return of +260.0%, while the worst single day was Sep 21, 2015 at -47.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.67% | -76.63% | -30.20% | -25.83% | 186.45% | -37.09% | -50.68% | -89.07% | |||||
| 2025 | 28.71% | -19.69% | -41.43% | 16.29% | 5.31% | -43.73% | -5.98% | -23.12% | -17.67% | 71.69% | -28.19% | -11.11% | -72.79% |
| 2024 | -6.96% | -6.59% | 53.85% | -26.25% | 7.34% | -3.68% | -1.09% | 2.33% | -43.31% | 3.81% | -60.55% | -31.63% | -83.62% |
| 2023 | 49.07% | -19.79% | -11.69% | -15.29% | -27.43% | 8.13% | 22.57% | -11.91% | -10.66% | -35.33% | -36.17% | 99.44% | -44.25% |
| 2022 | -34.77% | -16.91% | -9.29% | -48.78% | -36.15% | -22.79% | -5.83% | -15.57% | -40.00% | -34.79% | 1.55% | -1.53% | -96.14% |
| 2021 | 74.11% | -7.18% | -48.62% | 1,238.71% | -71.08% | 25.07% | -36.20% | 5.05% | -22.95% | -8.39% | -30.16% | -29.92% | -6.92% |
Benchmark Metrics
Eterna Therapeutics Inc has an annualized alpha of 13.71%, beta of 0.52, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since October 19, 1992.
- This stock participated in 210.29% of S&P 500 Index downside but only 37.11% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.52 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 13.71%
- Beta
- 0.52
- R²
- 0.01
- Upside Capture
- 37.11%
- Downside Capture
- 210.29%
Return for Risk
Risk / Return Rank
ERNA ranks 8 for risk / return — above 8% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Eterna Therapeutics Inc (ERNA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ERNA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.02 | ||
| Sortino ratioReturn per unit of downside risk | -3.51 | ||
| Omega ratioGain probability vs. loss probability | 0.82 | 1.25 | -0.43 |
| Calmar ratioReturn relative to maximum drawdown | -0.99 | 2.00 | -3.00 |
| Martin ratioReturn relative to average drawdown | -1.47 | 8.49 | -9.97 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Eterna Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Eterna Therapeutics Inc was 100.00%, occurring on Jul 31, 2026. The portfolio has not yet recovered.
The current Eterna Therapeutics Inc drawdown is 100.00%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-100.00%Jul 2026 | 33y 1mo | — | 33y 1moJun 1993 - now | — |
-25.92%Apr 1993 | 21d | 29d | 1mo 20dMar 1993 - May 1993 | — |
-18.47%Dec 1992 | 19d | 1mo 13d | 2mo 2dDec 1992 - Feb 1993 | — |
-17.28%May 1993 | 5d | 1mo 12d | 1mo 17dMay 1993 - Jun 1993 | — |
-14.77%Oct 1992 | 8d | 6d | 14dOct 1992 - Nov 1992 | — |
Drawdown Indicators
| ERNA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -93.02% | -9.10% | -83.92% |
Max Drawdown (3Y)Largest decline over 3 years | -99.70% | -18.90% | -80.80% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | -25.43% | -74.57% |
Max Drawdown (10Y)Largest decline over 10 years | -100.00% | -33.92% | -66.08% |
Current DrawdownCurrent decline from peak | -100.00% | -1.58% | -98.42% |
Average DrawdownAverage peak-to-trough decline | -86.20% | -10.70% | -75.50% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 62.71% | 2.14% | +60.57% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Eterna Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Eterna Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ERNA in comparison with other companies in the Biotechnology industry. Currently, ERNA has a P/B value of 0.4. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ERNA
Add Eterna Therapeutics Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ERNA